Ann Lab Med.  2021 Mar;41(2):240-242. 10.3343/alm.2021.41.2.240.

der(1)t(1;1)(p36;q10) as a Rare Variant of 1q Gain in Fanconi Anemia-Associated Myelodysplastic Syndrome

• Safavi M
• Vasei M

• KMID: 2512672
• DOI: http://doi.org/10.3343/alm.2021.41.2.240

Figure

• 

  Fig. 1 Cytogenetic analysis. (A) Chromosomal breakage analysis revealed increased chromosomal breaks and triradial formation (mitomycin C stress analysis results=0.96 breaks/cell). (B) Karyotyping of synchronized bone marrow culture using the Giemsa trypsin banding method showed 45,XY,der(1)t(1;1)(p36;q10),-7[18]/46XY[2].

• 

  Fig. 2 Histological analysis. (A) The bone marrow biopsy demonstrated a hypercellular marrow with an increased number of dysplastic micromegakaryocytes (hematoxylin and eosin, ×400). (B) The reticulin stain revealed increased marrow fibrosis (×400). (C) Immunohistochemistry for factor VIII-related antigen demonstrated increased unilobular and hypolobular megakaryocytes (counterstained with hematoxylin and eosin, ×400). (D) Immunohistochemistry for CD34 stained 4–5% of the cells (counterstained with hematoxylin and eosin, ×400).

Reference

1. Cioc AM, Wagner JE, MacMillan ML, DeFor T, Hirsch B. 2010; Diagnosis of myelodysplastic syndrome among a cohort of 119 patients with Fanconi anemia: morphologic and cytogenetic characteristics. Am J Clin Pathol. 133:92–100. DOI: 10.1309/AJCP7W9VMJENZOVG. PMID: 20023263. PMCID: PMC5467447.

2. Harmsen T, Riepsaame J, Alexantya G, van Mil SE, de Vries Y, et al. , van de Vrugt HJ. 2019; Effective CRISPR/Cas9-mediated correction of a Fanconi anemia defect by error-prone end joining or templated repair. Sci Rep. 9:768. DOI: 10.1038/s41598-018-36506-w. PMID: 30683899. PMCID: PMC6347620.

3. Quentin S, Cuccuini W, Ceccaldi R, Nibourel O, Pondarre C, Pagès MP, et al. 2011; Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. Blood. 117:e161–70. DOI: 10.1182/blood-2010-09-308726. PMID: 21325596.

4. Karner K, George TI, Patel JL. 2019; Current aspects of clonal hematopoiesis: implications for clinical diagnosis. Ann Lab Med. 39:509–14. DOI: 10.3343/alm.2019.39.6.509. PMID: 31240877. PMCID: PMC6660325.

5. A ZamecnikovaS al Bahar. 2017; der(1)t(1;1)(p36;q11-q32) in hematopoietic malignancies. Atlas Genet Cytogenet Oncol Haematol. 21:150–5. DOI: 10.4267/2042/68235.

6. de Latour RP, Soulier J. 2016; How I treat MDS and AML in Fanconi anemia. Blood. 127:2971–9. DOI: 10.1182/blood-2016-01-583625. PMID: 27020090.

7. Fu B, Jaso JM, Sargent RL, Goswami M, Verstovsek S, Medeiros LJ, et al. 2014; Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems. Mod Pathol. 27:681–9. DOI: 10.1038/modpathol.2013.187. PMID: 24186132.

8. Della Porta MG, Travaglino E, Boveri E, Ponzoni M, Malcovati L, Papaemmanuil E, et al. 2015; Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia. 29:66–75. DOI: 10.1038/leu.2014.161. PMID: 24935723.

9. Duhoux FP, Ameye G, Montano‐Almendras CP, Bahloula K, Mozziconacci MJ, Laibe S, et al. 2012; PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies. Br J Haematol. 156:76–88. DOI: 10.1111/j.1365-2141.2011.08918.x. PMID: 22050763.